Question

Mix-Tech is developing a vaccine for rotavirus that should provide adaptive immune protection for infection through the digestive tract. During phase 3 clinical trials, they did a large study of IgA-deficient patients to see if this candidate vaccine worked in these patients.

From what you have learned, briefly explain why these patients would be important to test during these clinical trials.

Answer 1

Total virus vaccine is a vaccine used to protect against rotavirus infections,which are the leading cause of severe diarrhea among young children.The vaccine prevent 15-34% of severe diarrhea in the developing world and 37-96% of severe diarrhea in the developed world.

Immunoglobulin A(IgA) deficiency is a genetic immunodeficiency,a type of hypogammaglobulinemia.People with this deficiency lack immunoglobulin A(IgA), a type of antibody that protects against infections of the mucous membranes lining the mouth,airways, and digestive tract.

IgA is proposed to be essential to control rotavirus disease,so it is important to do a clinical trial on individuals with IgA deficiency to see how they modulate rotavirus and immune responses.